Facing questions on patient deaths, Aurinia shares crater in wake of lupus study
Aurinia Pharmaceuticals managed to kick up a brief spike in its share price this morning after releasing some upbeat numbers from a Phase IIb study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
